Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Leukemia, Myeloid, Acute 103 Leukemia 53 Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Lymphoma 29 Prostatic Neoplasms 28 Leukemia, Monocytic, Acute 26 Leukemia, Erythroblastic, Acute 23 Congenital Abnormalities 23 Leukemia, Myelomonocytic, Acute 22 Leukemia, Megakaryoblastic, Acute 21 Myelodysplastic Syndromes 17 Lymphoma, Non-Hodgkin 17 Lymphoma, Follicular 17 Lymphoma, Large B-Cell, Diffuse 16 Recurrence 14 Lymphoma, Large-Cell, Immunoblastic 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Leukemia, Biphenotypic, Acute 9 Lymphoma, Mantle-Cell 8 Burkitt Lymphoma 7 Breast Neoplasms 7 Anemia, Refractory, with Excess of Blasts 6 Neoplasms 5 Leukemia, Promyelocytic, Acute 5 Hodgkin Disease 5 Blast Crisis 5 Ovarian Neoplasms 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia, Eosinophilic, Acute 4 Leukemia, Basophilic, Acute 4

Interventions

Magnetic Resonance Spectroscopy 10 Iodine-131 8 selpercatinib 5 Thyrotropin Alfa 5 trametinib 4 dabrafenib 4 Vemurafenib 4 Thyroidectomy 4 lenvatinib 3 cabozantinib 3 Transurethral Resection of Prostate 3 Sunitinib 3 Specimen Handling 3 Sorafenib 3 Radiofrequency Ablation 3 Fluorodeoxyglucose F18 3 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3 vandetanib 2 entrectinib 2 cobimetinib 2 X-Rays 2 Trastuzumab 2 Thyroid (USP) 2 Surgical Procedures, Operative 2 Rosiglitazone 2 Radiotherapy 2 Nivolumab 2 Lymph Node Excision 2 Interviews as Topic 2 Gefitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Cancer, Papillary × Mitoxantrone × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡